Tar, nicotine and carbon monoxide yield of UK cigarettes and the risk of non-muscle-invasive and muscle-invasive bladder cancer.

Frits H M van Osch, Charlotte G G M Pauwels, Sylvia H J Jochems, Ranti Fayokun, Nicholas D James, D Michael A Wallace, Kar-Keung Cheng, Richard T Bryan, Frederik J van Schooten, Maurice P Zeegers

Journal: European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP) 2019;28(1):40-44

PMID: 28683008

Abstract

Cigarette smoking is a major risk factor for bladder cancer (BC); however, the impact of cigarette content remains unclear. This study aims to investigate tar, nicotine and carbon monoxide (TNCO) yields of different filtered cigarettes in relation to BC risk. From the Bladder Cancer Prognosis Programme 575 non-muscle-invasive bladder cancer (NMIBC) cases, 139 muscle-invasive bladder cancer (MIBC) cases and 130 BC-free controls with retrospective data on smoking behaviour and cigarette brand were identified. Independently measured TNCO yields of cigarettes sold in the UK were obtained through the UK Department of Health and merged with the Bladder Cancer Prognosis Programme dataset to estimate the daily intake of TNCO. BC risk increased by TNCO intake category for NMIBC cases (P <0.050 in all multivariate models), but only for the daily intake of tar for MIBC cases (P=0.046) in multivariate models. No difference in risk was observed between smokers of low-tar/low-nicotine and high-tar/high-nicotine cigarettes compared with never smokers, either for NMIBC (P=0.544) or MIBC (P=0.449). High daily intake of TNCO additionally increases the risk of both NMIBC and MIBC compared with low daily intake. However, as there is no difference in BC risk between low-tar/low-nicotine and high-tar/high-nicotine cigarette smokers, it remains unclear whether smoking behaviour or TNCO yield of cigarettes explains this association.

Address: Department of Complex Genetics and Epidemiology.; Institute of Cancer and Genomic Sciences.; Department of Pharmacology and Toxicology, NUTRIM School for Nutrition and Translational Research in Metabolism.; Centre for Health Protection, National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands.; Department of Medicine, Centre for Pharmacology and Therapeutics, Division of Experimental Medicine, Imperial College London, London, UK.; Department of Urology, University Hospital Birmingham, NHS Foundation Trust, Birmingham.; Department of Public Health and Epidemiology, University of Birmingham.; Department of Complex Genetics and Epidemiology, CAPHRI School for Public Health and Primary Care, Maastricht University, Maastricht.
Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.